Literature DB >> 18268124

Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer.

Thomas A Sellers1, Yifan Huang, Julie Cunningham, Ellen L Goode, Rebecca Sutphen, Robert A Vierkant, Linda E Kelemen, Zachary S Fredericksen, Mark Liebow, V Shane Pankratz, Lynn C Hartmann, Jeff Myer, Edwin S Iversen, Joellen M Schildkraut, Catherine Phelan.   

Abstract

Studies suggest that underglycosylation of the cell membrane mucin MUC1 may be associated with epithelial ovarian cancer. We identified 26 genes involved in glycosylation and examined 93 single nucleotide polymorphisms (SNP) with a minor allele frequency of > or =0.05 in relation to incident ovarian cancer. Cases were ascertained at the Mayo Clinic, Rochester, MN (n = 396) or a 48-county region in North Carolina (Duke University; n = 534). Ovarian cancer-free controls (n = 1,037) were frequency matched to the cases on age, race, and residence. Subjects were interviewed to obtain data on risk factors and a sample of blood for DNA and genotyped using the Illumina GoldenGate assay. We excluded subjects and individual SNPs with genotype call rates of <90%. Data were analyzed using logistic regression, with adjustment for age and residence. We fitted dominant, log additive, and recessive genetic models. Among Caucasians, nine SNPs in eight genes were associated with risk at P < 0.05 under at least one genetic model before adjusting for multiple testing. A SNP in GALNT1 (rs17647532) was the only one that remained statistically significant after Bonferroni adjustment for multiple testing but was not statistically significant in Hardy-Weinberg equilibrium among controls. Haplotype analyses revealed a global association of GALNT1 with risk (P = 0.038, under a recessive genetic model), which largely reflected a decreased risk of one haplotype (0.10 frequency; odds ratio, 0.07; P = 0.01) compared with the most common haplotype (0.39 frequency). These results suggest that genetic polymorphisms in the glycoslyation process may be novel risk factors for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18268124      PMCID: PMC3303215          DOI: 10.1158/1055-9965.EPI-07-0565

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  33 in total

1.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

2.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

3.  Reproductive, genetic, and dietary risk factors for ovarian cancer.

Authors:  M Mori; I Harabuchi; H Miyake; J T Casagrande; B E Henderson; R K Ross
Journal:  Am J Epidemiol       Date:  1988-10       Impact factor: 4.897

4.  Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee.

Authors:  A S Whittemore; M L Wu; R S Paffenbarger; D L Sarles; J B Kampert; S Grosser; D L Jung; S Ballon; M Hendrickson
Journal:  Am J Epidemiol       Date:  1988-12       Impact factor: 4.897

5.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

Authors:  H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod
Journal:  Am J Hum Genet       Date:  2001-02-15       Impact factor: 11.025

Review 6.  Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity.

Authors:  L V Hooper; J I Gordon
Journal:  Glycobiology       Date:  2001-02       Impact factor: 4.313

Review 7.  MUC1 and the MUCs: a family of human mucins with impact in cancer biology.

Authors:  Stephan E Baldus; Katja Engelmann; Franz-Georg Hanisch
Journal:  Crit Rev Clin Lab Sci       Date:  2004       Impact factor: 6.250

Review 8.  All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.

Authors:  Kelly G Ten Hagen; Timothy A Fritz; Lawrence A Tabak
Journal:  Glycobiology       Date:  2002-11-01       Impact factor: 4.313

Review 9.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

Review 10.  MUC1: a multifunctional cell surface component of reproductive tissue epithelia.

Authors:  Melissa Brayman; Amantha Thathiah; Daniel D Carson
Journal:  Reprod Biol Endocrinol       Date:  2004-01-07       Impact factor: 5.211

View more
  29 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.

Authors:  Joellen M Schildkraut; Ellen L Goode; Merlise A Clyde; Edwin S Iversen; Patricia G Moorman; Andrew Berchuck; Jeffrey R Marks; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Julie M Cunningham; Robert A Vierkant; David N Rider; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Xiaoqing Chen; Catherine Phelan; Rebecca Sutphen; Thomas A Sellers; Leigh Pearce; Anna H Wu; David Van Den Berg; David Conti; Christopher K Elund; Rebecca Anderson; Marc T Goodman; Galina Lurie; Michael E Carney; Pamela J Thompson; Simon A Gayther; Susan J Ramus; Ian Jacobs; Susanne Krüger Kjaer; Estrid Hogdall; Jan Blaakaer; Claus Hogdall; Douglas F Easton; Honglin Song; Paul D P Pharoah; Alice S Whittemore; Valerie McGuire; Lydia Quaye; Hoda Anton-Culver; Argyrios Ziogas; Kathryn L Terry; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger; Brian Calingaert; Stephen Chanock; Mark Sherman; Montserrat Garcia-Closas
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

3.  Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer.

Authors:  Houda Bouanene; Hassen Hadj Kacem; Leila Ben Fatma; Halima Ben Limem; Slim Ben Ahmed; Salwa Yakoub; Abdelhédi Miled
Journal:  Pathol Oncol Res       Date:  2010-11-03       Impact factor: 3.201

4.  The challenge of determining the impact of FUT3 tumor-associated polymorphism rs2306969 (-6951 C> T) in invasive breast cancer cells.

Authors:  Jessica Catarine Frutuoso do Nascimento; Anderson de Oliveira Vasconcelos; Maria Aparecida Barreto Lopes Seabra; Eduardo Isidoro Carneiro Beltrão; Cíntia Renata Costa Rocha
Journal:  Mol Biol Rep       Date:  2019-03-30       Impact factor: 2.316

5.  Single-nucleotide polymorphisms in the lysyl oxidase-like protein 4 and complement component 3 genes are associated with increased risk for endometriosis and endometriosis-associated infertility.

Authors:  Lynnette A Ruiz; Julie Dutil; Abigail Ruiz; Jessica Fourquet; Sonia Abac; Joaquín Laboy; Idhaliz Flores
Journal:  Fertil Steril       Date:  2011-07-05       Impact factor: 7.329

6.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

7.  Novel association of polymorphic genetic variants with predictors of outcome of catheter ablation in atrial fibrillation: new directions from a prospective study (DECAF).

Authors:  Sanghamitra Mohanty; Amelia W Hall; Prasant Mohanty; Sameer Prakash; Chintan Trivedi; Luigi Di Biase; Pasquale Santangeli; Rong Bai; J David Burkhardt; G Joseph Gallinghouse; Rodney Horton; Javier E Sanchez; Patrick M Hranitzky; Amin Al-Ahmad; Vishwanath R Iyer; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2016-01       Impact factor: 1.900

8.  Risk of ovarian cancer and inherited variants in relapse-associated genes.

Authors:  Abraham Peedicayil; Robert A Vierkant; Lynn C Hartmann; Brooke L Fridley; Zachary S Fredericksen; Kristin L White; Elaine A Elliott; Catherine M Phelan; Ya-Yu Tsai; Andrew Berchuck; Edwin S Iversen; Fergus J Couch; Prema Peethamabaran; Melissa C Larson; Kimberly R Kalli; Matthew L Kosel; Vijayalakshmi Shridhar; David N Rider; Mark Liebow; Julie M Cunningham; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

9.  GEOGLE: context mining tool for the correlation between gene expression and the phenotypic distinction.

Authors:  Yao Yu; Kang Tu; Siyuan Zheng; Yun Li; Guohui Ding; Jie Ping; Pei Hao; Yixue Li
Journal:  BMC Bioinformatics       Date:  2009-08-25       Impact factor: 3.169

10.  Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.

Authors:  J M Cunningham; R A Vierkant; T A Sellers; C Phelan; D N Rider; M Liebow; J Schildkraut; A Berchuck; F J Couch; X Wang; B L Fridley; A Gentry-Maharaj; U Menon; E Hogdall; S Kjaer; A Whittemore; R DiCioccio; H Song; S A Gayther; S J Ramus; P D P Pharaoh; E L Goode
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.